Objective Low-dose trimethoprim-sulfamethoxazole (TMP-SMX) is commonly used to prevent pneumocystis pneumonia in daily practice. Previous reports have shown a relationship between high-or standard-dose of TMP-SMX and hyperkalemia, however it remains unclear whether this is true for low-dose TMP-SMX. In this study we sought to determine the risk factors for hyperkalemia associated with low-dose TMP-SMX. Methods In this retrospective cohort study, 186 consecutive adult patients who received TMP-SMX as prophylaxis for pneumocystis pneumonia from January 2014 to January 2015 were evaluated. Data on the patients' age, gender, baseline estimated glomerular filtration rate (eGFR), baseline serum potassium, maximum serum potassium, duration reaching the maximal serum potassium level, dosage, and concomitant use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB), β-blockers, nonsteroidal anti-inflammatory drugs and potassium-sparing diuretics were retrospectively collected. Hyperkalemia was defined as a serum potassium level ! 5 mEq/L. Univariate and multivariate analyses were performed. Results The median age of the patients was 66 years and 51.1% were men. Hyperkalemia associated with low-dose TMP-SMX was observed in 32 patients (17.2%). The median duration to reach the maximal serum potassium level was 12 days. The multivariate logistic regression analysis identified renal insufficiency to be a major risk factor for hyperkalemia associated with low-dose TMP-SMX (eGFR <60 mL/min/1.73 m 2 , adjusted OR 4.62). Moreover, in the subpopulation of patients with renal insufficiency, ACEi/ARB use was considered to be a major risk factor for hyperkalemia (adjusted OR 3.96). Conclusion Renal insufficiency in concert with ACEi/ARB use is a major risk factor for hyperkalemia induced by low-dose TMP-SMX.
Introduction
Trimethoprim-sulfamethoxazole (TMP-SMX) consists of two antimicrobial agents that act synergistically against a wide variety of bacteria (1) (2) (3) (4) (5) (6) . TMP-SMX is also widely used as prophylaxis for pneumocystis pneumonia (7) . The recommended dose for this purpose is 80 mg TMP and 400 mg SMX per day or three times per week (7) . Approximately 70% of SMX is protein-bound, while it is partially acetylated (61%) and glucuronide-conjugated (15%) in the liver. In contrast, TMP is excreted into the urine in its unchanged form. TMP causes the blockage of amiloridesensitive sodium channels in the collecting duct and acts as a potassium-sparing diuretic (8) (9) (10) (11) (12) that may lead to fatal adverse effects of TMP-SMX (13) . Mild hyperkalemia (serum potassium level <6 mEq/L) is generally required for a close follow-up and avoidance of a high intake of potassium. It also often requires modification of the current concomitant therapies that might increase the potassium levels. Severe hyperkalemia could lead to cardiac arrhythmias and arrest, along with fatal outcomes (14) . Previous studies with different designs showed a relationship between TMP-SMX and hyperkalemia (15) (16) (17) (18) (19) (20) . Most of these studies, however, evaluated the association between high-or standard-dose TMP-SMX and hyperkalemia and identified older age, renal insufficiency and concomitant administration of other prescription drugs with TMP-SMX to be risk factors for hyperkalemia (8, 17, 18, 20) . Little is known about the association between low-dose TMP-SMX (TMP <80 mg/ day) (8) and hyperkalemia. TMP 80 mg/day is commonly used in daily practice as prophylaxis for pneumocystis pneumonia, thus we defined low-dose TMP-SMX as TMP ! 80 mg/day in the present study.
In this study, we demonstrate that renal insufficiency in concert with ACEi/ARB use is a major risk factor for hyperkalemia associated with low-dose TMP-SMX.
Materials and Methods

Patients
A retrospective cohort study was conducted among 186 consecutive adult patients (age " 20 years) who received TMP-SMX for the first time as prophylaxis for pneumocystis pneumonia from January 2014 to January 2015 at the secondary referral hospital in Ehime, Japan. Within the study period, 467 adults received TMP-SMX. The following patients were excluded: (1) those who had been previously prescribed TMP-SMX (n=16), (2) those with a therapeutic dose of TMP-SMX (n=77), (3) those missing data on the serum potassium level within 30 days after receiving TMP-SMX (n=68), (4) those with a serum potassium level " 5 mEq/L when starting TMP-SMX (n=18), and (5) those undergoing hemodialysis (n=9). Patients were also excluded if they received a larger dose than TMP 80 mg and SMX 400 mg per day for prophylaxis (n=5) or their blood data at least once a week were not available (n=88).
Data collection
Data on the patient's age, gender, underlying disease, baseline estimated glomerular filtration rate (eGFR), baseline serum potassium level, maximum serum potassium level, duration of maximal serum potassium level, dosage (TMP 80 mg or 40 mg per day), concomitant use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB), β-blockers, non-steroidal antiinflammatory drugs (NSAIDs), and potassium-sparing diuretics were retrospectively collected. ACEi/ARB, β-blockers and potassium-sparing diuretic were used for hypertension, chronic heart failure, arrhythmia and diabetes. Hyperkalemia was defined as a serum potassium level " 5 mEq/L (21, 22) . The baseline potassium level was obtained at the beginning of treatment with TMP-SMX. If the data of the serum potassium level were not available on the first day of TMP-SMX, then the closest previous data on the serum potassium level prior to the initiation of TMP-SMX treatment were used as the baseline serum potassium level. The laboratory data were obtained from day 5 to day 30 after receiving TMP-SMX. This study was conducted in accordance with the Declaration of Helsinki and its amendments. The protocol was approved by the Ethics Committee of Matsuyama Red Cross Hospital.
Statistical analysis
Univariate and multivariate analyses were performed. Fisher's exact test was used for comparison of the proportions, while a t-test was used for continuous variables. Multivariate logistic regression analyses were conducted. Variables with p values less than 0.2 in the univariate analyses were subsequently subject to a multivariate analysis. All analyses, including the confidence intervals were two-sided, and a p<0.05 was considered to be statistically significant. All statistical analyses were performed using the EZR software package (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for the R software program (The R Foundation for Statistical Computing, version 2.13.0) (23) .
Results
A total of 186 patients were included in the analyses. The baseline characteristics are summarized in Table 1a . The median age of the patients was 66 years, and 51.1% were men. More than half of the patients were elderly (" 65 years: 60.8%). TMP-SMX was mainly used for patients with concomitant clinical conditions such as hematological, rheumatic, respiratory or kidney diseases. The mean (SD) eGFR was 72.5 (29.9) mL/min/1.73 m 2 and 30.1% of the patients had renal insufficiency (eGFR <60 mL/min/1.73 m 2 ). Patients who were treated with ACEi/ARB, β-blockers, NSAIDs, potassium-sparing diuretics or steroids concomitantly with TMP-SMX were 23.7%, 11.8%, 8.6%, 3.2%, 86.0%, respectively. A total of 150 patients (80.6%) were prescribed TMP-SMX at the dose of TMP 80 mg/SMX 400 mg per day. The prophylactic dose of TMP-SMX was decided at the physicians' discretion.
The changes associated with potassium after starting TMP-SMX are shown in Table 1b . The median maximal level of serum potassium was 4.4 (range 3.3-6.2) mEq/L and the median duration to reach the maximum level of serum potassium was 12 days. The median change from baseline to the maximum level of serum potassium (ΔK) was 0.4 (range, -1 to 2.4) mEq/L. Thirty-two of 186 patients (17.2%) developed hyperkalemia. A significant difference in the ΔK was found between the groups with hyperkalemia We next investigated the risk factors for hyperkalemia associated with low-dose TMP-SMX. Age, renal insufficiency, and the use of ACEi/ARB were statistically associated with hyperkalemia in the univariate analyses ( Table 2 ). The multivariate analysis, however, identified renal insufficiency to be the major risk factor for hyperkalemia (adjusted OR 4.62) ( Table 3) .
Moreover, in the subpopulation of patients with renal insufficiency, ACEi/ARB use and male gender were found to be additional risk factors for hyperkalemia [ACEi/ARB adjusted OR (95% CI): 3.96 (1.17-13.4); male gender: 3.77 (1.12-12.7); Table 4 and 5].
Discussion
The current study identified that patients with renal insufficiency (17.2%) are at risk for hyperkalemia associated with low-dose TMP-SMX (TMP 80 mg/day).
Despite the usage at a higher dose than in our study, previous studies showed the association between TMP-SMX and hyperkalemia. Gentry et al. demonstrated that renal insufficiency was a risk factor for hyperkalemia (defined as ! 5.5 mEq/L) in patients with standard-(TMP <5 mg/kg/day) and high-dose (TMP ! 5 mg/kg/day) TMP-SMX (20) . In cases of TMP <320 mg/day, patients with a serum creatinine level >1.2 (mg/dL) exhibited significantly higher levels of maximum serum potassium (24) . Taken together, our current findings indicate that renal dysfunction greatly puts patients at risk for hyperkalemia irrespective of the dosage of TMP-SMX. In kidney diseases, an impaired production of aldosterone results in abdominal potassium excretion (25, 26) . Accordingly, the potassium-sparing effects of TMP-SMX are presumably accentuated in patients with kidney insufficiency even at low-dose TMP-SMX.
Our results are consistent with the findings of Mori et al., who showed 9.1% of patients treated with low-dose TMP-SMX (TMP <80 mg/day) exhibited hyperkalemia (serum potassium >5 mEq/L), which was the only previous report to show the association between low-dose TMP-SMX and hyperkalemia (8) . A possible explanation for the somewhat lower incidence of hyperkalemia in their study compared with ours may be due to the sample size analyzed (their study only included 11 patients).
Although ACEi/ARB use, age (! 65 years) and potassiumsparing diuretics are risk factors for hyperkalemia with highdose TMP-SMX (17, 18, 20, 27) , our study shows that this is not the case for hyperkalemia associated with low-dose TMP-SMX. Our results showed that in patients with renal insufficiency, ACEi/ARB use may be a risk factor for hyperkalemia associated with low-dose TMP-SMX. ACEi/ARB use potentially causes hyperkalemia via the inhibition of the renin-aldosterone system, the induction of an impaired extrarenal/transcellular potassium disposition, in addition to a reduction of potassium excretion with renal impairment (26, 28) . Indeed, in six separate clinical trials of more than 1,500 patients with chronic kidney disease (CKD), increased serum potassium levels of 0.3-0.6 mmol/L were observed in the ACEI-treated patients (29) .
Our findings also showed that male gender may be a risk factor for hyperkalemia associated with low-dose of TMP-SMX, albeit the association was not statistically significant. It should be noted that the plasma potassium concentration is increased by testosterone and amiloride, and TMP induces hyperkalemia in male mice (30) . Thus, male hormones, including testosterone, may enhance the potassium-sparing effects of low-dose TMP-SMX.
In our study, we assessed the serum levels of potassium from day 5 to day 30 after starting TMP-SMX prophylaxis. Antoniou et al. reported that serum potassium peaked at day 4 through 5 after starting high-dose TMP-SMX as the therapeutic agent (17) . Gentry et al. retrospectively investigated patients with hyperkalemia (serum potassium >5.5 mEq/L) within 30 days after starting TMP-SMX treatment and found that the highest level of potassium was obtained around day 3 (20) . According to the previous findings which showed that hyperkalemia associated with TMP-SMX is influenced by the dose of TMP-SMX (20, 31), we carefully determined the time point of blood sampling. In this study, although patients were given a low-dose TMP-SMX, hyperkalemia was observed at a median of 12 days to reach similar levels of serum potassium reported by Gentry et al (12.1 days) (20) . Our results suggest that serum electrolytes should be evaluated within 1 to 2 weeks in patients treated with low-dose of TMP-SMX.
Low-dose TMP-SMX is very effective for the prophylaxis of pneumocystis pneumonia with a high prevention rate (7) . Although this drug is used worldwide in routine clinical practice, there have been very few reports on the association between low-dose TMP-SMX and hyperkalemia, and the associated risk factors, such as age, renal function, and the presence of concomitant drugs. Given that this is a singlecenter study with Japanese patients alone, our findings may not be generalize to other populations. Therefore, further studies are necessary to confirm our findings. However, renal insufficiency was clearly shown to be the major risk factor for hyperkalemia associated with low-dose TMP-SMX, and ACEi/ARB use was an additional risk factor for hyperkalemia in patients with renal insufficiency. Because immunocompromised patients are frequently given low-dose TMP-SMX for prophylaxis of pneumocystis pneumonia, the presence or absence of renal insufficiency must be determined in these patients. Furthermore, ACEi/ARB is widely used in patients with renal insufficiency because blockage of the renin-angiotensin-aldosterone system reduces proteinuria and GFR decline (32) . Taken together, our current findings suggest that patients with renal insufficiency should be carefully monitored for hyperkalemia when receiving TMP-SMX for prophylaxis of pneumocystis pneumonia, especially in conjunction with ACEi/ARB.
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